Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution to Timolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma - Investigation on the Efficacy and Safety of Carteolol/Latanoprost Combination Ophthalmic Solution in Patients with Glaucoma

Miyata Eye Hospital0 个研究点目标入组 15 人开始时间: 2017年12月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients are excluded from participation if any of the following criteria apply. For criteria relating to the eye, patients are excluded when one eye meets any of the criteria. 1)Patients with highest corrected visual acuity of 0.2 or lower 2)Patients who are not able to discontinue the use of contact lens during the evaluation period 3)Patients who have been administered the following drugs within 28 days before the initiation of the evaluation period: Beta blocker (instillation, systemic) Treatment drug for hypertension Corticosteroids (other than local dermal administration in sites other than the eyelid) Drugs with contraindications for glaucoma (anticholinergic agents such as scopolamine, mazindol, etc.) 4)Patients for whom new use or change of treatment drugs for glaucoma or OH (instillation or systemic, excluding the assigned study drug) is scheduled during the evaluation period 5)Patients with hypersensitivity to components of ophthalmic solution that contain carteolol hydrochloride, timolol maleate, or latanoprost and others

发起方